



FOR IMMEDIATE RELEASE

PPD Ranked as a Top Business Technology Innovator

WILMINGTON, N.C., (May 3, 2016) – Pharmaceutical Product Development, LLC ([PPD](#)) today announced it has been named for the fifth time to the InformationWeek Elite 100, a list of the top business technology innovators in the United States.

“PPD’s recognition validates our commitment to accelerating the pace of innovation in research and harnessing new and innovative approaches to help speed the delivery of life-changing therapies,” said Mike Wilkinson, executive vice president and chief information officer for PPD. “PPD helps our clients build a global approach to clinical trials and technology that better engages and encourages patient participation in clinical trials.”

PPD’s technology features disruptive innovations, including utilizing wearable or mHealth technology, and [Preclarus®](#), PPD’s portfolio of solutions that consolidates and standardizes clinical trial data from multiple sources, giving clients transparent, real-time access to all clinical trial operations and patient data.

“As business success becomes even more dependent on the ability to innovate in information technology, being represented on the InformationWeek Elite 100 list is one of the biggest honors a company can achieve,” said Susan Nunziata, editorial director of *InformationWeek* magazine. “It’s a validation of efforts by the business to make IT a game changer.”

InformationWeek identifies and honors the nation's most innovative users of information technology. The InformationWeek Elite 100 research tracks the technology-based investments, strategies and results of some of the best-known organizations in the country, spotlighting the power of business technology innovation.

About PPD

PPD is a leading global [contract research organization](#) providing comprehensive, integrated [drug development](#), [laboratory](#) and lifecycle management services. Our clients and partners include [pharmaceutical](#), [biotechnology](#), [medical device](#), academic and [government](#) organizations. With offices in 46 countries and more than 15,000 professionals worldwide, PPD applies innovative technologies, therapeutic expertise and a firm commitment to quality to help clients and partners bend the cost and time curve of drug development to deliver life-changing therapies that improve health. For more information, visit www.ppd.com.

PPD Contacts

Media:

Elizabeth Humphrey

+1 910 558 6096

elizabeth.humphrey@ppdi.com

Investors:
Nate Speicher
+1 910 558 6783
nate.speicher@ppdi.com

Except for historical information, all of the statements, expectations and assumptions, including statements, expectations and assumptions about PPD's award-winning technology contained in this news release are forward-looking statements that involve a number of risks and uncertainties. Although PPD attempts to be accurate in making these forward-looking statements, it is possible that future circumstances might differ from the assumptions on which such statements are based and could cause actual results to differ materially from the forward-looking statements. Other important factors that could cause future results to differ materially include the following: rapid technological advances that make our services or capabilities less competitive; risks associated with and dependence on strategic relationships; risks associated with acquisitions and investments; the ability to attract, integrate, retain and train key personnel; competition in the outsourcing industry; PPD's ability to win new business; overall global economic conditions; economic conditions, research and development spending, and outsourcing trends in the pharmaceutical, biotechnology and government-sponsored research sectors; loss, delay or modification of large contracts; higher-than-expected cancellation rates; the rate of conversion of backlog into revenue; consolidation in the pharmaceutical and biotechnology industries; the ability to control SG&A spending; compliance with drug development regulations; changes in the regulation of the drug development process; and actual operating performance. PPD assumes no obligation and expressly disclaims any duty to update these forward-looking statements in the future, except as required by applicable law. These forward-looking statements should not be relied upon as representing PPD's estimates or views as of any date subsequent to the date hereof.

###